

A photograph of two surgeons in an operating room. They are wearing blue scrubs, blue bouffant caps, and white face masks. The surgeon on the left is in the foreground, looking down at a piece of medical equipment with a coiled cable. The surgeon on the right is slightly behind and to the side, also looking down. The background is a plain, light-colored wall.

EDITED BY
Lawton Robert Burns

India's Healthcare Industry


Innovation in Delivery,
Financing, and Manufacturing

CAMBRIDGE

India's Healthcare Industry

*Innovation in Delivery, Financing, and
Manufacturing*

Edited by
Lawton Robert Burns



CAMBRIDGE
UNIVERSITY PRESS

CAMBRIDGE UNIVERSITY PRESS

4381/4 Ansari Road, Daryaganj, Delhi 110002, India

Published in the United States of America by Cambridge University Press, New York

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9781107044371

© Cambridge University Press 2014

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2014

Printed in India Shree Maitrey Printech Pvt. Ltd., Noida

*A catalogue record for this publication is available from the British Library
Library of Congress Cataloging-in-Publication Data*

India's healthcare industry : innovation in delivery, financing, and
manufacturing / [edited by] Lawton Robert Burns.

p. ; cm.

Includes bibliographical references and index.

Summary: "Describes the three sets of institutions that deliver healthcare services in India, finance these services, and manufacture the products used in these services"--Provided by publisher.

ISBN 978-1-107-04437-1 (hbk.) -- ISBN 978-1-107-62234-0 (pbk.)

I. Burns, Lawton R., editor of compilation.

[DNLM: 1. Delivery of Health Care--India. 2. Biomedical Technology--India. 3. Health Care Sector--India. 4. Health Services--India. W 84 J14]

RA529

362.10954--dc23

2013030728

ISBN 978-1-107-04437-1 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

To Lee, Alex, and Bud

with love

✂

To God Almighty

with many thanks

Preface

This volume grew out of an experiment at the Wharton School's MBA program: to have Wharton faculty teach global modular courses (GMCs) to Wharton students on specific topics all around the world. The idea of the GMCs is to provide students with a unique combination of local immersion, course concepts, and understanding of emerging business issues. The topics and locations of these courses are chosen to give students first-hand exposure to business challenges and opportunities in regions undergoing rapid change – for example, energy and infrastructure in Brazil, global supply chain management in China, and marketing in emerging economies such as India and China.¹

The first such course offered was HCMG 890, “Innovation in the Indian Healthcare Industry.” Wharton faculty and students developed the content for the course in collaboration with industry experts from across India. Their collective effort is presented here. This volume seeks to describe the current state of India's healthcare system ranging from the parties that *pay* for healthcare (individuals who pay out of pocket, insurance companies, community insurance schemes, government ministries), the parties that *provide* healthcare (hospitals, physicians, and diagnostic laboratories), and the parties that *produce* the products used in healthcare delivery (pharmaceuticals, biotechnology, and medical devices). The volume also includes discussion of innovative efforts to raise capital for the development of these sectors (e.g., private equity and venture capital), to deliver care to those at the “bottom of the pyramid,” to balance the population's ability to pay with their desire for access to modern care and technology, and to deliver care to foreign tourists. As such, this represents an effort to capture the components of the “value chain” of healthcare in India. In prior works, Wharton faculty have captured portions of the US healthcare value chain; this represents our first effort to go global.²

At first, it seems daunting (and perhaps presumptuous) to attempt to describe the healthcare system of a foreign country that one has never lived in. I have spent over 30 years studying and conducting research on my own country's healthcare system, beginning during my doctoral student days in the late 1970s. I have taught an introductory course on the US healthcare system since the early 1980s, and taught the required first-year core course to all entering MBA

healthcare majors at Wharton since the late 1990s. In that course, we explicitly cover the payers, providers, and producers of healthcare – from a domestic angle as well as an international angle – all, by necessity, in 14 weeks. The Wharton students are increasingly drawn from a global pool, are the brightest and most demanding students I have ever had the privilege to teach, and historically have been more interested in the product side of the industry (pharmaceuticals, biotechnology, medical devices) than the payer and provider side (where most faculty like myself trained and have field experience). After more than 30 years of considerable effort, I feel I am beginning to understand how it all works (or doesn't) and just how “systemic” it really is.

Thus, despite my lack of sustained exposure to and formal training in other healthcare contexts, I have had to confront how other countries finance and deliver healthcare to their populations. I have also had the privilege of training (and working on research projects with) an increasingly international student body, and learning from them as I go. When the Wharton School asked me to travel to the Indian School of Business (ISB) to teach a course on India's healthcare system to ISB and Wharton students, I suspected that some (though not all) of the learning gathered on how systems work in the US might be transferable, but that I might also be able to discern important differences. After all, India has many states and a central federal government that split financial responsibility for healthcare, as in the US. India also has an entrepreneurial class of physicians (many of them western trained) and for-profit hospital executives who are pursuing many of the innovative strategies observed in the US system. At the same time, India has historically lacked the wealth of the US and has thus developed innovative financing and delivery systems that balance cost and access better than their counterparts in the US.

After several visits to India and other Asian countries (such as China, where I now teach a second GMC on their healthcare system at Guanghua School of Management at Peking University) to study their healthcare systems and talk with academics and industry experts, I have confirmed that the similarities outweigh the differences. I have concluded that governments around the world grapple with a similar set of issues in financing and delivering healthcare: how to balance the ultimate goals of improving health status, financial risk protection, and consumer satisfaction (the WHO model) or improving the experience of care, improving the health of populations, and reducing per capita costs of healthcare (the “triple aim” pursued in US healthcare reform).³ The frameworks used to analyze national healthcare systems and engineer their goals (policy levers and intermediate outcomes) are also broadly applicable (e.g., to countries like India and China). Finally, I have concluded that these countries face many of the same concerns and problems, utilize many of the same strategies to address these issues, and possess many of the same dynamics between major players on the financing, delivery, and product development sides.

This volume represents my effort to demonstrate these contentions. More importantly, it is intended to educate practitioners and executives who operate and/or do business in India in order to provide them with a “system view.” I have learned through several decades of experience studying the US system that parties occupying one part of the *value chain* (payers, providers, producers – and the intermediaries who separate them) rarely understand the motivations and strategies of the others, which leads to enormous conflicts and misalignment of incentives.

Such a value chain (or system) view is not presented in other recent texts on India's healthcare industry.⁴ This volume is designed to educate all parties about one another.

Notes

1. For more information, see: <http://www.wharton.upenn.edu/global/gmc.cfm>. Accessed October 13, 2011.
2. Lawton Robert Burns. *The Business of Healthcare Innovation*. Cambridge, UK: Cambridge University Press (2012); Lawton Robert Burns and Wharton School Colleagues. *The Health Care Value Chain*. San Francisco, CA: Jossey-Bass (2002).
3. Donald Berwick, Thomas Nolan, and John Whittington. "The Triple Aim: Care, Health, and Cost." *Health Affairs* 27(3) (2008): 759–769.
4. Brijesh Purohit. *Health Care System in India*. New Delhi: Gayatri Publications (2010); Kabir Sheikh and Asha George. *Health Providers in India*. New Delhi: Routledge (2010); Girish Kumar. *Health Sector Reforms in India*. New Delhi: Manohar Publishers (2009).

Acknowledgments

This book is the serendipitous result of interest on the part of individuals at both Wharton and the Indian School of Business in studying the vibrant healthcare industry in India. At Wharton, Harbir Singh, Vice Dean for Wharton's Global Initiatives, encouraged me to teach the Global Modular Course (GMC) on India's healthcare industry. Anjani Jain and Ziv Katalan, both on Wharton's faculty, were deeply involved in the Global Initiatives and spurred me to develop a course in tandem with ISB. Anjani and Ziv handled much of the logistics involved in putting on a course such as this. I am so grateful they accompanied me to Hyderabad during its first iteration at ISB as I became acclimated to "The Indian Way." As the healthcare program in Mohali took off, Jagmohan Raju lent invaluable help in navigating the interstices between Wharton and ISB.

To develop the content for such a course was a daunting task for someone unfamiliar with the country and its healthcare system. In fashioning the course curriculum and lecture material, I necessarily relied on a lot of people who had studied the topic for some time. These included my Wharton teaching assistants, most of whom were Indian and had worked in the industry, or had studied various sectors in India: (in alphabetical order) Sarah Frew, Prashanth Jayaram, Kalyan Pamarthy, Neil Parikh, Vimala Raghavendran Aditi Sen, Vishwas Seshadri, and Bhuvan Srinivasan. They also included my Wharton colleagues, like Jitendra Singh who gave me the book he coauthored on *The India Way* just as I set off to teach in India for the first time. I have also learned a considerable amount from the healthcare industry executives who came to speak to my ISB class or sent me a considerable amount of background reading material (again, in alphabetical order): Pervez Ahmed, Ashok Alexander, Ajay Bakshi, Sofi Bergkvist, Ashoke Bhattacharjya, Shefali Chhachhi, Amita Chebbi, Deepanwita Chattopadhyay, Krishna Ella, Zeena Johar, Ashok Kakkar, Deepa Krishnan, Preetha Reddy, Suneeta Reddy, Varaprasad Reddy, Varun Sahni, Devi Shetty, Shivender Singh, A. Vaideesh, and Vishal Vasishth, and the CEOs of LV Prasad Eye Institute and Gandhi Government Hospital in Hyderabad. Finally, I wish to thank some of my friends in the consulting and investment communities who shared with me presentations on India's healthcare industry: Jay Desai, Karl Kellner, Paul Mango, and Ajit Singh.

Indian School of Business Dean Ajit Rangnekar and Deputy Dean Savita Mahajan graciously hosted the Wharton Global Modular Course at the Hyderabad campus in January 2010 and 2011 and even allowed ISB students to enroll in it. Special thanks go to Ashalata Devi, Associate Director at ISB. She has served as my main point of contact these past 3 years and solved all of my course issues.

I gratefully acknowledge the support of Analjit Singh, Founder and Chairman of Max India Limited, who spearheaded the development of a healthcare management program at ISB's new campus in Mohali. It was Analjit who catalyzed my decision first to teach at the campus in Hyderabad, and later to serve as the program's first area leader. Analjit's generosity has made all of the above possible.

Every author knows the singular importance of a good editor and editorial help. Many thanks to Chris Harrison at Cambridge University Press for adroitly seeing the potential of a volume like this, and to Suvadip Bhattacharjee and Ranjini Majumdar for seeing it through with alacrity. My administrative assistant, Holly Cronin, did excellent work in editing this entire volume. I hired her almost entirely for this task and she has exceeded all of my expectations.

Finally, I want to thank my wife, Alexandra, who initially suggested to me that I ought to get more "global" in my research and consider countries like India. Like many husbands, I heeded her suggestion a bit later than I should have, but here I am at last.

Contents

<i>List of Figures</i>	vii
<i>Preface</i>	xv
<i>Acknowledgments</i>	xix

SECTION I

Introduction: Lenses and Frameworks for Analyzing India's Healthcare System

1. India's Healthcare Industry: A System Perspective	3
<i>Lawton Robert Burns</i>	
2. Innovative Responses to the Healthcare Challenges Confronting India	38
<i>Stephen M. Sammut</i>	
3. India's Healthcare Industry: An Overview of the Value Chain	59
<i>Lawton Robert Burns</i>	

SECTION II

Providers: Delivery of Healthcare Services

4. The Medical Profession in India	141
<i>Ajay Bakshi and Lawton Robert Burns</i>	
5. India's Hospital Sector: The Journey from Public to Private Healthcare Delivery	169
<i>Lawton Robert Burns, Bhuvan Srinivasan and Mandar Vaidya</i>	
6. Medical Tourism: Opportunities and Challenges	219
<i>Lawton Robert Burns, Prashanth Jayaram and Richa Bansal</i>	
7. The Aravind Eye Care System	290
<i>R. Carter Clement, Arunavo Roy, Ravi Shah, James Calderwood and Lawton Robert Burns</i>	

8. The Real Deal at L V Prasad Eye Institute: Excellence and Equity in Healthcare 317
Sashi Mohan Athota, Matthew Abel, Nessa Feller, Prasad Kilaru, Raghu Kodige, Vikram Lal, Meghna Shyam Varma, Richa Wilson and Rob Zwolinski
9. Vaatsalya Healthcare: Promoting Access to Healthcare in Rural and Semi-Urban India 335
Colleen Murphey

SECTION III

Payers: Financing of Healthcare Services

10. The Health Insurance Sector in India: History and Opportunities 361
Aditi Sen, Jessica Pickett and Lawton Robert Burns
11. Providing Care to the Bottom of the Pyramid 400
Neil Parikh and Vimala Raghavendran
12. Opportunities in Healthcare Private Equity in India 424
Aman Kumar

SECTION IV

Producers: Manufacturers of Healthcare Technology

13. The Indian Pharmaceutical Sector: The Journey from Process Innovation to Product Innovation 441
Vishwas Seshadri
14. India's Biotechnology Sector 477
Sarah Frew
15. The Medical Device Sector in India 500
Lawton Robert Burns, Tanmay Mishra, Kalyan Pamarthy and Arunavo Roy
16. Balancing Access and Innovation in Developing Countries 538
Ashoke Bhattacharjya and Brian Corvino

- Contributors* 561
- Index* 569

List of Figures

1.1	The Iron Triangle of Health Care: Balancing Act among Intermediate Outcomes	4
1.2	India and US: Convergences in Healthcare Systems	8
1.3	India vs. US: Divergences in Healthcare Systems	10
1.4	The Millennium Preston Curve	11
1.5	Health Care Financing Structures in China and India in 2005	13
1.6	Age Distributions in China and India	14
1.7	Policy Levers, Intermediate Outcomes, and Ultimate Ends of a Health System	16
1.8	Government Initiatives to Drive Behavioral Change, from Disseminating Information to Prohibiting Behavior	18
1.9	The Health Care Value Chain	18
1.10	The Value Chain in India	19
1.11	The Health Care Quadrilemma	20
1.12	India States and Population Growth	22
1.13	Lifestyle and Chronic Diseases by Inpatient/Outpatient Treatment	26
1.14	Shimmering and Shivering India Households	27
1.15	Financial Allocations for Health Sectors in India Between 1951 and 1997	29
2.1	Interventional Programs for Maternal and Child Health Over the Last 40 Years.	46
2.2	National Policies for Chronic Diseases and Injuries in India	49
2.3	Intervention Strategies Categorized by Level of Health System and Cost Effectiveness.	51
3.1	India's Regulatory Body	62
3.2	Total Health Expenditure in India as a Percentage of GDP	65

3.3	Total Health Expenditure in India as a Percentage of GDP, Broken Out by Private versus Public Spend	66
3.4	Total Health Expenditure as a Share of GDP, 2009 (or Nearest Year)	66
3.5	Total Health Expenditure Per Capita, Public and Private, 2009 (or Nearest Year)	67
3.6	Projected Healthcare Spending in India (\$US in Billions)	67
3.7	Five Year Plans (FYPs) Expenditures	68
3.8	Government Investment in Healthcare and Other Sectors	69
3.9	Private Sector Involvement in India's Growing Healthcare Market	71
3.10	Out-of-Pocket Spend on Various Categories	71
3.11	Public Health Expenditure in India	72
3.12	Sources of Funding for India's Healthcare System	74
3.13	Sources of National Health Expenditures: Direct + Indirect Financing (2001–02 Data)	75
3.14	Destinations of National Health Expenditures (2001–02 Data)	76
3.15	Destinations of Out-of-Pocket Household Spending	78
3.16	Traditional and Modern Indian Medicine	81
3.17	Hospital Beds Per 1000 Population, 2000 and 2009 (or Nearest Year)	85
3.18	Government Initiatives to Improve Healthcare Infrastructure	88
3.19	India's Healthcare Workforce	94
3.20	Practising Doctors Per 1000 Population, 2009 and Change Between 2000 and 2009	99
3.21	Practising Nurses Per 1000 Population, 2009 and Change Between 2000 and 2009	100
3.22	Ratio of Nurses to Physicians, 2009 (or Nearest Year)	101
3.23	Growth in Health Insurance Coverage	108
4.1	Current Architecture of India's Health System	142
4.2	Details of Indian Public Health System Infrastructure	143
4.3	Indian Healthcare Providers Divided into Several Unique Segments	144
4.4	Trends in Medical Education, 1950–2004 (NISM – Allopathic)	149
4.5	Concentration of Medical Colleges in Southern States of India (2011)	149
4.6	The Long and Arduous Journey to Become a Doctor	154
4.7	Allopathic Physician's Qualifications	154
4.8	Two Parallel Tracks for Medical Education in India	155
4.9	Doctor Engagement Models in India	159
4.10	Physicians can be Segmented by Their Goals and Practice Behavior	161
4.11	Physicians Vary Significantly in the Financial Value they Bring to a Hospital	162
4.12	Government Agencies Have Multiple Interactions with Physicians	163
4.13	Mobile Technologies That Can Disrupt the Healthcare Delivery Model	165

5.1	Healthcare Spend by Government on a Steady Rise	170
5.2	India's Healthcare Spend Likely to Become Much Higher than Peer Benchmarks	171
5.3	Primary, Secondary, and Tertiary Care Levels	171
5.4	Increase in Household Income 2010–20	172
5.5	India Shortfall in Beds, Physicians and Nurses	173
5.6	India Lags behind Most Other Countries in Immunization Rates, at Full Immunization Rate of around 61 percent	174
5.7	Multiple Gaps Lead to Demand Leakages	175
5.8	Right Siting is Critical to Ensure Demand–Supply	176
5.9	Structure of NRHM (11th Five-Year Plan)	179
5.10	Hospital Inpatient Market Shares, by Public–Private and Rural–Urban	180
5.11	Imbalance in Bed Supply and Utilization	181
5.12	Public Share of Outpatient Market, by Rural–Urban	181
5.13	All-India Shortfall in Health Infrastructure	182
5.14	State Variations in Government-provided Hospital Beds	182
5.15	73 Percent of Total Funds Allocated by Central to State Government Used	183
5.16	Hospital Projects Funded by the IFC in US \$ Million	186
5.17	Vaatsalya Hospital Structure	188
5.18	Leading Hospital Players in India	193
5.19	Fortis Hospitals: Establishing Itself as a Multi-specialty National Chain	196
5.20	Fortis Hospitals: Escorts Acquisition Helped Fortis be EBITDA Positive	197
5.21	Fortis ARPOB Model	199
5.22	Fortis Combined Operations	204
5.23	Fortis Geographic and Business Diversification	205
5.24	Apollo Hospitals: Concentrated in South, Expanding to Other Regions	205
5.25	Apollo Hospitals: High Margins Despite Capacity and Regional Expansion	206
5.26	Apollo Hospitals: High Local Market Share to Drive Profitability	210
5.27	Max Healthcare: Regional Play – Underserved but Growing Locations	213
5.28	Max Healthcare: Turns EBITDA Positive FY08	214
5.29	Future Outlook for Private Hospital Sector	215
6.1	Medical Tourism: Historical Perspective	220
6.2	Cost Comparison by Procedure	221
6.3	Trade in the Health Sector	223
6.4	Definition of Medical Travel	228
6.5	Flow of Medical Tourists by Country	229
6.6	Balancing Price, Quality, and Service	230
6.7	Hypothesized Stages of Medical Tourism	232
6.8	Survey of Medical Travelers from around the World	234
6.9	Travel Costs in Medical Tourism	236

6.10	Flow Process for the Medical Tourist	239
6.11	The Medical Tourism System (MTS)	239
6.12	Physician Fees for Routine Office Visits: US, India, and Other Countries	241
6.13	MRI Imaging Fees: US, India, and Other Countries	241
6.14	JCI Accreditations by Country	242
6.15	US Medical Program Affiliations	244
6.16	Understanding the Payers in the US	245
6.17	Summary of Medical Tourism Offerings from Commercial Insurers	248
6.18	New AMA Guidelines on Medical Tourism	249
6.19	State Bills to Incentivize Medical Tourism	252
6.20	Stakeholder Perceptions Towards Medical Tourism	253
6.21	Patient Inflow to Indian Hospitals, by Country	260
6.22	Cost Comparison for CABG Between Three International Medical Tourism Providers	261
6.23	Top 10 Source Countries for Foreign Tourist Arrivals (FTAs) in India in 2009	262
6.24	JCI Accredited Organizations in India	263
6.25	Most Popular Treatments Sought in India by Medical Tourists	263
6.26	Broadening the List of Target Countries – for Indian Hospitals	265
6.27	Share of International Patients by Hospital	265
6.28	Essentials for Medical Tourism Success	267
6.29	Consumer Concerns	267
7.1	The Aravind Eye Care System, 2009	293
7.2	Aravind's Financial Results	294
7.3	Total Volume for Surgeries and Lasers	295
7.4	Surgical Quality at Aravind	296
7.5	Surgeon Productivity Comparisons (Annual Procedure Volume)	298
8.1	Causes of Blindness and Visual Impairment	320
8.2	LVPEI Eye Health Pyramid	321
8.3	Historical Patient Statistics at LVPEI	324
8.4	LVPEI Organization Structure	326
9.1	Purchasing Hydrochloride at Jaisalmer Pharmacy	336
9.2	Streets of Jaisalmer	337
9.3	Generic Injectable Adrenaline and Methylrednisone, Jaisalmer Pharmacy	339
9.4	Price List Posted by Physician Organization in Mandya Hospital Waiting Room	343
9.5	Mysore Hospital Nursing Station	345
9.6	Sample Profit and Loss (P&L) Exhibit A: Revenues	349
9.7	Sample Hospital Utilization Report (October 2011)	351
9.8	Prototype Electric Wheelchair	352

9.9	Designation of Separate Waste Bags Posted Above Scrub Sink in the OR	353
9.10	Questions Asked on Patient Feedback Call	354
10.1	Out-of-Pocket Spending is the Primary Source of Healthcare Spending in India	362
10.2	Indian General [Non-Life] Insurance Companies	363
10.3	The Fundamental Role of Health Plans is to Insure Members against Unexpected Financial Burdens of Medical Care	366
10.4	Historical Timeline of Health Insurance in India	369
10.5	Public Sector Insurance Companies Continue to Comprise about 60 percent of the Market but Stand-alone Insurers are Gaining Share	370
10.6	Emergence of Private Insurance Firms	373
10.7	Growth in Indian Insurance Market 2002–08	374
10.8	Organized Workforce in India is Historically Small, but Growing	375
10.9	Indian Insurance Value Chain	375
10.10	TPAs Primarily Administer Claims and Contract Provider Network Management for Insurers	376
10.11	National and State Health Insurance Coverage 2010	378
10.12	Population Covered by Health Insurance	379
10.13	Source of Revenue under Insurance Schemes	379
10.14	Ecosystem of Indian Insurance (Private Intermediation in the Indian Health Care Sector)	380
10.15	Three Types of Insurance Policies	381
10.16	Characteristics of Health Insurance Policies	382
10.17	Future Growth of the Health Insurance Industry	392
11.1	Estimates of Number Living Below Poverty Line (Millions)	402
11.2	Inequities in Health Status and Utilization	405
11.3	Public Health Care Facilities Run by the Municipality versus the Maharashtra State in Mumbai	406
11.4	Prahalad's Principles of Innovation for BOP	412
11.5	Business Models that Work	412
11.6	Yeshasvini Identity Card (RSBY)	413
11.7	Yeshasvini Enrollees (100,000), 2003–10	414
11.8	Premiums and Subsidy Per Yeshasvini Enrollee (Rs.), 2004–08	415
11.9	Surgical Volume Per Physician in Selected Cardiac Programs	417
11.10	Acumen Fund Equity Investments in India 2011	418
11.11	Acumen Investments	419
11.12	Acumen Fund's Portfolio (\$M under Management)	419
12.1	Recent Trends in PEVC Investments	427
12.2	Recent Notable Healthcare PEVC Deals	427

12.3	Pharmaceutical and Healthcare Deal-Making 2006–10	435
12.4	PEVC as a Cyclical Business	435
13.1	Evolution of the Indian Pharmaceutical Sector	443
13.2	Indian Pharmaceutical Domestic Market Sales Forecast	444
13.3	Sales and Sales Growth by Therapeutic Area in India	445
13.4	Domestic Market Share of Top 10 Competitors	446
13.5	USFDA ANDAs Filed by Top 10 Indian Pharmaceutical Firms	448
13.6	Total US FDA ANDAs Filed and Approved for Each Company till FY12	449
13.7	Recent Collaborative Deals Between Indian Companies and Foreign MNCs	451
13.8	Leading Eight Indian Pharmaceutical Companies Net Sales in Rupees Million by Rank, 2009–11.	453
13.9	Profit after Tax (Rs. Million)	454
13.10	Indian Pharmaceutical Companies Sales Rankings FY12	454
13.11	Ranbaxy's Top 10 Brands	455
13.12	Geographic Split of Ranbaxy's FY12 Global Sales	456
13.13	Geographic Split of Global Revenues FY12 – Dr Reddy's Laboratories	457
13.14	Sun Pharmaceuticals and Taro Revenue Mix FY11	460
13.15	Lupin's FY12 Revenue Mix	462
13.16	Lupin's FY12 Therapeutic Segments	463
13.17	Cipla Revenues by Therapeutic Area	465
13.18	Recent Acquisitions of Indian Companies by MNCs	467
13.19	A Comparison of Unit Manufacturing Cost of Formulated Chemical Drug Product Between US-based and Indian Formulation Plants	468
13.20	Traditional Bulk Drug and Formulation Clusters in India	469
13.21	G-CSF Price Trend after Entry of Biosimilars	472
13.22	G-CSF Market Expansion after Entry of Biosimilars	473
14.1	India Biotech Industry 2005–10 (\$MM)	479
14.2	Biotech Industry Exports vs. Domestic 2009–10 (\$MM)	479
14.3	Top Biotech Clusters (2009–10)	480
14.4	Biotech Industry Revenues by Segment (2009–10) – \$MM	481
14.5	BioPharma Revenues by Sub-Segment (2009–10)	482
14.6	India's Top 10 Domestic Biotech Companies (2009–10) – \$MM	482
14.7	Biocon Revenues by Segment (FY2006–10)	485
14.8	Biocon Financials FY2006–10 (\$MM)	486
14.9	Biocon Pipeline	487
14.10	Serum Institute of India's Exported Products	489
14.11	FY2009–10 Panacea Financial Performance Summary (\$MM)	491
15.1	Global Medical Device Market 2004–11	502
15.2	Projected Medical Device Market 2011–18	503